Claudins in Cancer: A Current and Future Therapeutic Target

Int J Mol Sci. 2024 Apr 24;25(9):4634. doi: 10.3390/ijms25094634.

Abstract

Claudins are a family of 27 proteins that have an important role in the formation of tight junctions. They also have an important function in ion exchange, cell mobility, and the epithelial-to-mesenchymal transition, the latter being very important in cancer invasion and metastasis. Therapeutic targeting of claudins has been investigated to improve cancer outcomes. Recent evidence shows improved outcomes when combining monoclonal antibodies against claudin 18.2 with chemotherapy for patients with gastroesophageal junction cancer. Currently, chimeric antigen receptor T-cells targeting claudin 18 are under investigation. In this review, we will discuss the major functions of claudins, their distribution in the normal as well as cancerous tissues, and their effect in cancer metastasis, with a special focus on the therapeutic targeting of claudins to improve cancer outcomes.

Keywords: CAR-T cell therapy; carcinoma; claudin; monoclonal antibodies; targeted therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Claudins* / metabolism
  • Epithelial-Mesenchymal Transition
  • Humans
  • Molecular Targeted Therapy / methods
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Neoplasms* / pathology
  • Tight Junctions / metabolism

Substances

  • Claudins

Grants and funding

This research received no funding.